For the continued treatment after surgery of the NSCLC patients with ALK negative primary tumors, 23 patients received further treatment (including chemotherapy and targeted agents), and 2 patients died; 19 patients survived, including the patients with ALK positive metastatic tumors, and 2 patients were lost to follow up; 7 patients did not receive further treatment, 3 patients survived, and 4 patients were lost to follow up; 3 patients received unknown treatment and died. Here, ALK is linked to metastatic neoplasm.